TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Vitamin C, Hydrocortisone and Thiamine in Patients With Septic Shock

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Above 18 years of age~* Sepsis of any background~* Vasopressor-dependent sepsis for at least 2 hours and vasopressor dose ≥ 0.25 µg / kg / min~Exclusion Criteria:~* Pregnancy;~* Requests for DNR (do not resuscitate) / DNI (do not intubate);~* Death is considered imminent or inevitable during this hospitalization and the attending physician, patient or substitute decision maker is not committed to active treatment;~* Patients with acute cerebral vascular event, acute coronary syndrome, active gastrointestinal bleeding, burn or trauma at admission;~* Patients with known HIV infection;~* Patients with known glucose-6 phosphate dehydrogenase (G-6PD) deficiency;~* Patients with septic shock transferred from another ICU or hospital with characteristics of septic shock for\> 12 hours;~* Patients with septic shock characteristics for\> 12 hours;~* Patients with a known history of oxalate nephropathy;~* Patients with short bowel syndrome or severe known fat malabsorption;~* Patients with acute beriberi disease;~* Patients with acute Wernicke's encephalopathy;~* Patients with known malaria;~* Patients with known or suspected scurvy;~* Patients with known or suspected Addison's disease;~* Patients with known Cushing's disease;~* Physician expects to prescribe or the patient has previously used (less than 15 days) systemic glucocorticoids for an indication other than septic shock (not including nebulized or inhaled corticosteroids), including the use of glucocorticoids for COVID-19;~* The patient is receiving treatment for systemic fungal infection or has documented Strongyloides infection at the time of randomization;~* Patient with known chronic iron overload due to iron storage and other diseases;~* Patient previously enrolled in this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention (Type: EXPERIMENTAL): 1,5 g of vitamin C every 6 hours + 200 mg of thiamine every 12 hours + 50 mg of hydrocortisone every 6 hours~For 7 days or until patient's discharge/death
- Control (Type: PLACEBO_COMPARATOR): Placebo 1 for vitamin C every 6 hours + Placebo 2 for thiamine every 12 hours + 50 mg of hydrocortisone every 6 hours~For 7 days or until patient's discharge/death

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Long-Term Follow-Up Study of Patients With Osteoarthritis of the Knee Treated With UBX0101 or Placebo

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with knee OA who have completed a randomized placebo-controlled study of UBX0101.~* Patients who are willing and able to consent to having blinded, long-term follow-up; consent via legally authorized representative is not accepted.~Exclusion Criteria:~* Patients with any condition that, in the opinion of the Investigator, would likely interfere with adhering to the study schedule of visits for 12 months.~* Patients who are scheduled to undergo knee arthroplasty on either knee during the study.~* Patients who anticipate arthroscopic surgery on either knee at any time during the study.~* Patients who plan to receive treatment with an anti-nerve growth factor agent during the study.~* Patients who plan to participate in another investigational study (including interventional studies of investigational drugs and investigational treatments \[e.g., braces, stem cells, and procedures\]) during the study.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Patients from a randomized placebo-controlled study of UBX0101 (Type: None): Patients with moderate to severe, painful OA of the knee who participated in a randomized, placebo-controlled study of UBX0101.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Radiographic and Clinical Outcomes of PureGen in Posterior Lumbar (PLIF) and Transforaminal Interbody Fusion (TLIF)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects with back and/or leg pain electing to receive Transforaminal Lumbar Interbody Fusion (TLIF)/ Posterior Lumbar Interbody Fusion (PLIF) procedure and posterior transpedicular stabilization with or without decompression at any level~* Unresponsive to conservative treatment for at least 6 months~* Radiographic confirmation of primary diagnosis~Exclusion Criteria:~* More than 2 levels requiring lumbar interbody fusion~* Spondylolisthesis greater than Grade I~* Prior failed fusion surgery at any lumbar level(s)~* Local or systemic infection past or present~* Active systemic disease~* Osteoporosis, osteomalacia, or other metabolic bone disease that would significantly inhibit bone healing~* BMI greater than 40~* Use of other bone graft, Bone Morphogenetic Protein (BMP) or bone graft substitutes in addition to or in place of those products specified~* Use of post operative Spinal Cord Stimulator (SCS)~* Any condition requiring postoperative medications that inhibit fusion, such as chronic use of oral or injected steroids or prolonged use of non-steroidal anti-inflammatory drugs~* Known or suspected history of alcohol and/or drug abuse~* Involved in pending litigation or worker's compensation related to the spine~* Pregnant or plans to become pregnant during the course of the study~* Insulin-dependent diabetes mellitus~* Known sensitivity to device materials~* Life expectancy less than duration of study~* Any significant psychological disturbance that could impair consent process or ability to complete self-assessment questionnaires~* Undergoing chemotherapy or radiation treatment~* Known history of hypersensitivity or anaphylactic reaction to dimethyl sulfoxide (DMSO)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lumbar Degenerative Disc Disease (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Post-operative Radiotherapy With Cisplatin Alone or in Combination With Iressa in Upper Aerodigestive Tract Carcinomas

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with upper aerodigestive tract carcinomas (all sites included) having surgical resection and eligible for post-operative radiation + cisplatin.~* Patient having a tumoral biopsy (0.5 - 1 cm3) stored in liquid nitrogen at time of surgical resection (patients with small tumors located in larynx for instance will not be included)~* Patients receiving post-operative radiation (\>=60 Gy on tumor bed and/or cervical area), associated with cisplatin, 6 weeks after surgery at the latest.~Exclusion Criteria:~* previous history of cancer (except skin basal cell carcinoma)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- postop chemoradio with cisplatin (Type: ACTIVE_COMPARATOR): postoperative chemoradiotherapy with cisplatin
- postop chemoradio (cisplatin)+gefitinib (Type: EXPERIMENTAL): postoperative chemoradiotherapy with cisplatin + gefitinib

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Citalopram on Chest Pain in Patients With Functional Chest Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent~* Minimum age: 18 years~* Functional chest pain according to Rome IV criteria~* Ruled out cardiac origin of chest pain~* ECG with corrected QT interval (QTc) within the normal range (\<450ms male, \<460ms female)~* Symptoms of chest pain for at least 6 months~* Frequency of symptoms at least once a week~* Gastroduodenoscopy, high-resolution manometry and 24-hour pH-impedance monitoring need to have been performed recently.~Exclusion Criteria:~* Currently using antidepressants~* Contraindication for the use of SSRI~* Already tried antidepressants off-label to treat chest pain~* Known allergy to citalopram~* Severe and clinically unstable concomitant disease~* Pregnant, lactating or fertile women (without contraception)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Citalopram 20mg (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Acceptability and Persistence of the Use of a Patient-centred E-health Tool for Lupus Patients Followed in a Specialised Centre in France

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adult \> 18 years old~* Having given oral consent for participation~* Confirmed systemic lupus diagnosis (ACR criteria)~* Regular follow-up in the centre for more than 12 months~* With Internet access at home~* Affiliated with national health insurance system or other system~Exclusion Criteria:~* Persons subject to a legal protection measure (curatorship, guardianship)~* Persons subject to limited judicial protection~* Adults who are incapable or unable to express their consent~* Patients who cannot read French~* Patients whose cognitive status does not allow them to track their health data on a digital platform~* Patients to be followed up in another centre within 12 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Respiratory Event-Related Potentials in Patients With Spinal Cord Injury

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Participants with spinal cord injury (n = 20) will be age 30-60 years with motor complete spinal cord injuries, otherwise known as American Spinal Injury Association (ASIA) classification A or B, between the levels of C3 and T12. Subjects will be divided equally into four different injury level categories. The four categories are high tetraplegia (C3 - C5), low tetraplegia (C6-C8), high paraplegia (T1-T6), and low paraplegia (T7-T12). Twenty healthy age-matched adults will also participate.~Exclusion Criteria:~* History or presence of lung disease (asthma, chronic bronchitis, etc)~* Current smoker (more than one cigarette per day the past year)~* History of traumatic brain injury, epilepsy, or seizure; using psychotropic medication of any type~* And, if patient, more than six months since spinal cord injury and clinically stable.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Spinal Cord Injury (Type: None): Participants with spinal cord injury (n = 20) will be age 30-60 years with motor complete spinal cord injuries, otherwise known as American Spinal Injury Association (ASIA) classification A or B, between the levels of C3 and T12. Patients will have to be able to breathe independently without the use of a ventilator. Subjects will be divided equally into four different injury level categories. The four categories are high tetraplegia (C3 - C5), low tetraplegia (C6-C8), high paraplegia (T1-T6), and low paraplegia (T7-T12).
- Controls (Type: None): Twenty healthy age-matched adults will also participate.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Moderate Sedation Educational Software

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CROSSOVER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* general nursing staff at the University of Utah~* currently required to obtain moderate sedation training~* an equal basis all clinicians in the respective departments~Exclusion Criteria:~* nurses and other personnel who do not administer moderate sedation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 2 (Type: None): web based learning group
- 1 (Type: None): paper based learning group

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of Irinotecan & Capecitabine in Metastatic Colorectal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed metastatic colorectal cancer~* ECOG performance status 0-2~* Mesurable lesions~* No prior chemotherapyk or radiotherapy for metastatic disease. Prior radiotherapy is permitted if it was not administered to target lesions selected for this study and provided it has been completed at least 4 weeks before registration~* Adjuvnat chemo or radiotherapy was completed at least 6 months prior to start study treatment~* Adequate organ functions~* Expected survival is longer then 6 months~* Informed consent~Exclusion Criteria:~* Prior systemic chemotherapy for metastatic disease~* Prior treatment with oxaliplatin or irinotecan~* CNS metastases~* Uncontrolled or severe cardiovascular disease~* Serious concurrent infection or nonmalignant illness that is uncontrolled or whose control may be jeopardized by complications of study therapy~* Other malignancy within the past 3 years except cured non-melanomatous skin cancer or carcinoma in situ of the cervix~* Psychiatric disorder or uncontrolled seizure that would preclude compliance~* Pregnant, nursing women or patients with reproductive potential without contraception~* Patients receiving a concomitant treatment with drugs interacting with capecitabine such as flucytosine, phenytoin, or warfarin et al.~* Prior unanticipated severe reaction to fluoropyrimidine therapy, or known dihydropyrimidine dehydrogenase (DPD) deficiency~* Major surgery within 3 weeks prior to study treatment starts, or lack of complete recovery from the effects of major surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: King Video Laryngoscope Versus Direct Laryngoscopy for Prehospital Intubation: A Randomized Controlled Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* all patients \>= age 18 year of age undergoing ETI in the prehospital setting~Exclusion Criteria:~* age \< 18 years of age

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Video Laryngoscopy (Type: EXPERIMENTAL): We will outfit ½ of the ambulance crews with the King Video Laryngoscope (KVL) for 6 months while the other ½ of the ambulances will use traditional direct laryngoscopy (DL). After 6 months, the groups will switch devices. We will randomly assign those ambulances that first use the KVL. After one year (12 months) we will compare the outcomes between the two methods.
- Direct Laryngoscopy (Type: ACTIVE_COMPARATOR): We will outfit ½ of the ambulance crews with the King Video Laryngoscope (KVL) for 6 months while the other ½ of the ambulances will use traditional direct laryngoscopy (DL). After 6 months, the groups will switch devices. We will randomly assign those ambulances that first use the KVL. After one year (12 months) we will compare the outcomes between the two methods.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Bioavailability and Safety Study of Probuphine Versus Sublingual Buprenorphine in Patients With Opioid Dependence

Study Design Characteristics:
- Allocation: None
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Voluntarily provide written informed consent prior to the conduct of any study related procedures~* Male or female, 18-75 years of age~* Meet the DSM-IV criteria for current opioid dependence~* Females of childbearing potential and fertile males must use a reliable means of contraception~Exclusion Criteria:~* Current diagnosis of Acquired Immune Deficiency Syndrome (AIDS)~* Received treatment for opioid dependence (e.g., methadone, BPN) within the previous 90 days~* Current diagnosis of chronic pain requiring opioids for treatment~* Candidates for only short term opioid treatment or opioid detoxification therapy~* Pregnant or lactating females~* Previous hypersensitivity or allergy to BPN or EVA-containing substances or naloxone~* Current use of agents metabolized through Cytochrome P450 3A4 (CYP 3A4) such as azole antifungals (e.g., ketoconazole), macrolide antibiotics (e.g., erythromycin), and protease inhibitors (e.g., ritonavir, indinavir, and saquinavir)~* Current history of coagulopathy, and/or anti-coagulant therapy (such as warfarin)~* Meet the DSM-IV criteria for current dependence on any other psychoactive substances other than opioids or nicotine (e.g., alcohol, sedatives)~* Current use of benzodiazepines other than physician prescribed use~* Significant medical or psychiatric symptoms, cognitive impairment, or other factors which in the opinion of the Investigators would preclude compliance with the protocol, patient safety, adequate cooperation in the study, or obtaining informed consent~* Concurrent medical conditions (such as severe respiratory insufficiency) that may prevent the patient from safely participating in study; and/or any pending legal action that could prohibit participation and/or compliance in study~* Participated in a clinical study within the previous 8 weeks~* Previous participation in a Probuphine clinical trial~* Presence of aspartate aminotransferase (AST) levels greater than or equal to 3 X upper limit of normal and/or alanine aminotransferase (ALT) levels greater than or equal to 3 X upper limit of normal and/or total bilirubin greater than or equal to 1.5 X upper limit of normal and/or creatinine greater than or equal to 1.5 X upper limit of normal~* Clinically significant low platelet count with current history of coagulopathy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Probuphine (Type: EXPERIMENTAL): Patients are first inducted on SL BPN, and then switched to 4 Probuphine implants

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Cardiac Strain Using Speckle Tracking Echocardiography During Orthotopic Liver Transplantation

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age greater than 18 years~* Undergoing primary orthotopic liver transplantation~Exclusion Criteria:~* Redo orthotopic transplantation~* Acute or fulminant liver failure~* Patient with pre-existing atrial fibrillation or hypertrophic cardiomyopathy~* Patients with an abnormal preoperative stress test (EF \<55%, areas of prior infarct, ongoing ischemia)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy